Full text is available at the source.
Abstract
Tirzepatide, a dual GIP/GLP-1 receptor agonist, may offer greater metabolic and anti-inflammatory benefits than conventional GLP-1 receptor agonists.
- Obesity is a significant risk factor for developing degenerative aortic stenosis (AS).
- No pharmacologic therapy has been proven to prevent the onset of AS.
- The potential impact of tirzepatide on the risk of incident AS is currently unknown.
Simplified